Preprint Article Version 1 Preserved in Portico This version is not peer-reviewed

Percutaneous Radiofrequency Ablation with or without Chemolipiodolization for Early-stage Hepatocellular Carcinoma: A Propensity Score-matched Analysis

Kota Takaki
,
Masahito Nakano
* ORCID logo ,
Kazuta Fukumori
,
Yoichi Yano
,
Yuki Zaizen
,
Takashi Niizeki
,
Kotaro Kuwaki
,
Masaru Fukahori
,
Takahiko Sakaue
,
Sohei Yoshimura
,
Mika Nakazaki
,
Takuji Torimura
Version 1 : Received: 3 October 2021 / Approved: 4 October 2021 / Online: 4 October 2021 (10:19:37 CEST)

How to cite: Takaki, K.; Nakano, M.; Fukumori, K.; Yano, Y.; Zaizen, Y.; Niizeki, T.; Kuwaki, K.; Fukahori, M.; Sakaue, T.; Yoshimura, S.; Nakazaki, M.; Torimura, T. Percutaneous Radiofrequency Ablation with or without Chemolipiodolization for Early-stage Hepatocellular Carcinoma: A Propensity Score-matched Analysis. Preprints 2021, 2021100038. https://doi.org/10.20944/preprints202110.0038.v1 Takaki, K.; Nakano, M.; Fukumori, K.; Yano, Y.; Zaizen, Y.; Niizeki, T.; Kuwaki, K.; Fukahori, M.; Sakaue, T.; Yoshimura, S.; Nakazaki, M.; Torimura, T. Percutaneous Radiofrequency Ablation with or without Chemolipiodolization for Early-stage Hepatocellular Carcinoma: A Propensity Score-matched Analysis. Preprints 2021, 2021100038. https://doi.org/10.20944/preprints202110.0038.v1

Abstract

We aimed to compare prognostic factors for overall survival (OS) following percutaneous radiofrequency ablation (PRFA) with or without chemolipiodolization (CL) for early-stage hepatocellular carcinoma (HCC) using propensity score-matched analysis. We enrolled 221 patients with early-stage HCC who received PRFA with (n = 76) or without (n = 145) CL in Saga Central Hospital between April 2004 and December 2020. No significant difference was observed in OS between PRFA with and without CL cohorts (median survival time [MST]: 5.4 vs. 4.5 years; p = 0.0806). To reduce confounding effects, 108 patients were selected using propensity score-matched analysis (n = 54 for each treatment). No significant difference was observed in OS between the cohorts (MST: 3.6 vs. 4.0 years; p = 0.5474). After stratification according to tumor size, no significant difference was observed in OS for patients with tumor size ≥20 mm between PRFA with and without CL cohorts (MST: 3.4 vs. 3.5 years; p = 0.8236). PRFA with CL was not a significant prognostic factor in both univariate and multivariate analyses (p = 0.5477 and 0.9600, respectively). Our findings suggest that PRFA with CL does not demonstrate longer prognostic effects than PRFA without CL in early-stage HCC, regardless of tumor size.

Keywords

hepatocellular carcinoma; percutaneous radiofrequency ablation; chemolipiodolization; risk factors; propensity score-matched analysis

Subject

Medicine and Pharmacology, Oncology and Oncogenics

Copyright: This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Download PDF

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.

Leave a public comment
Send a private comment to the author(s)
* All users must log in before leaving a comment
Views 0
Downloads 0
Comments 0
Metrics 0
Get PDF Cite Share 0
Bookmark BibSonomy Mendeley Reddit Delicious
×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.